Transcutaneous Vagal Nerve Stimulation in Treatment-Resistant Depression: A Feasibility Study.
BACKGROUND: Major depression (MD) contributes significantly to the global burden of disease with up to one-third of patients being treatment resistant. Therefore, the development of new treatment options for treatment-resistant depression (TRD) is needed. Vagus nerve stimulation (VNS) has shown mood improvements in patients with TRD. However, due to high costs related to the implantation and the invasive nature of VNS, an application with transcutaneous VNS (tVNS) has been developed stimulating a vagal nerve branch in the earlobe (Arnold’s nerve). A few studies with t-VNS in MD has shown a possible antidepressant effect, but feasibility is poorly described and patients with TRD have not been investigated.
OBJECTIVES: As the full antidepressant effect of t-VNS takes months we wanted to assess feasibility and side effects of daily treatments.
MATERIALS AND METHODS: Single-arm feasibility trial assessing compliance, usability, side effects, cognitive speed, and depression in a four-week period with a recommended t-VNS stimulation duration of four hours per day in patients with TRD. The primary outcome was compliance with 80% of the recommended daily treatment time.
RESULTS: Compliance threshold was reached for 80.0% of the 20 included participants. Usability was acceptable. Side effects were few, mild or moderate, mostly as local effects at the contact point in the ear. The device was difficult to use for some participants. A statistically significant reduction in depression severity and an increase in cognitive speed were seen with unchanged suicidal ideation and sleep.
CONCLUSIONS: We would recommend larger long-term randomized studies of t-VNS to access any antidepressant effect in TRD. The design of the device might be improved for higher usability.
PMID: 33539635 [PubMed – as supplied by publisher]
Neuromodulation. 2021 Feb 04;:
Authors: Evensen K, Jørgensen MB, Sabers A, Martiny K